Gastric cancer vaccine - OncoTherapy Science

Drug Profile

Gastric cancer vaccine - OncoTherapy Science

Alternative Names: OTSGC-A24

Latest Information Update: 07 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoTherapy Science
  • Developer National University Hospital (Singapore); OncoTherapy Science
  • Class Cancer vaccines; Peptide aptamers; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Gastric cancer

Most Recent Events

  • 07 Apr 2017 No recent reports of development identified - Phase-II for Gastric cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Singapore, South Korea, and Japan (SC)
  • 22 Mar 2016 The National University Hospital (Singapore) completes a phase I/II trial in Gastric cancer in Japan, South Korea and Singapore (NCT01227772,
  • 01 Jan 2015 Immunogenicity and adverse events data from a phase I/IIa trial in Gastric cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) presented at the ASCO Gastrointestinal Cancers Symposium 2015 (ASCO-GCS 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top